Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lx-101

Phase 2

MM.D. Anderson Cancer Center

Lx-101 is one of 24 therapeutic programs targeting Ewing sarcoma. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

23

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ewing SarcomaNot yet recruiting

Ewing SarcomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

23 competitors in Ewing Sarcoma

#DrugCompanyPhaseTrials

Verzenio

Lynparza

Oncovin

Zinecard

Vepesid

Ifex

BBaxter Healthcare Corporation

Cytoxan

BBaxter Healthcare Corporation

Camptosar

Zepzelca

Jazz Pharmaceuticals

Stivarga

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2033

Phase 2Not yet recruiting

Ewing Sarcoma

NCT07781891

Clinical

Trials by Indication[1]

Ewing sarcoma1 trial

Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07781891·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lx-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lx-101. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Related News